bosentan anhydrous has been researched along with sildenafil citrate in 207 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 78 (37.68) | 29.6817 |
| 2010's | 114 (55.07) | 24.3611 |
| 2020's | 15 (7.25) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Møller, GM; Ren, X; Wharton, J; Wilkins, MR | 1 |
| Maloney, JP | 1 |
| Fraisse, A; Habib, G | 1 |
| Faulenbach, C; Golpon, H; Hoeper, MM; Niedermeyer, J; Welte, T; Winkler, J | 1 |
| Banya, WA; Gibbs, JS; Gin-Sing, W; Mohiaddin, RH; Ng, LL; Nihoyannopoulos, P; Paul, GA; Pennell, DJ; Stefanidis, A; Strange, JW; Tunariu, N; Westwood, MA; Wilkins, MR | 1 |
| Behrends, M; Beiderlinden, M; Peters, J | 1 |
| Akhter, P; Bowen, M; McKenna, P; Molelekwa, V; Walsh, K | 1 |
| Hoeper, MM; McLaughin, VV | 1 |
| Abbas, A; Boobis, AR; Gibbs, JS; Paul, GA; Wilkins, MR | 1 |
| Clark, A; Morice, AH; Mulrennan, S | 1 |
| Naeije, R | 1 |
| Channick, RN; Lee, SH | 1 |
| Chakinala, MM | 1 |
| Behr, J; Borst, MM; Ghofrani, A; Halank, M; Hoeper, M; Klose, H; Stähler, G; Wilkens, H; Winkler, J | 1 |
| Hoeper, MM; Markevych, I; Niedermeyer, J; Spiekerkoetter, E; Welte, T | 1 |
| Kayser, SR | 1 |
| Ewert, R; Halank, M; Hoeffken, G; Kolditz, M; Opitz, C | 1 |
| Champion, HC; Hemnes, AR | 1 |
| Binkert, C; Clozel, M; Hess, P; Iglarz, M; Qiu, C; Rey, M | 1 |
| Archer, SL; Michelakis, ED | 1 |
| Coyne, TC | 1 |
| Berger, F; Ewert, P; Fehske, W; Gilbert, N; Lange, PE; Lunze, K; Mebus, S; Miera, O; Mühler, EG; Schulze-Neick, I; Uhlemann, F | 1 |
| Arroliga, AC; Minai, OA | 1 |
| Rich, S | 1 |
| Sastry, BK | 1 |
| Champion, HC; Fisher, MR; Girgis, RE; Hassoun, PM; Housten-Harris, T; Mathai, SC; Zaiman, A | 1 |
| Aranda, A; Ballesteros, S; Cabezón, S; Hinojosa, R; Lage, E; Mogollón, MV; Ordóñez, A; Sobrino, JM | 1 |
| Amantéa, SL; Ricachinevsky, CP | 1 |
| Wilkens, H | 1 |
| Ghofrani, HA; Hoeper, MM | 1 |
| Guillevin, L | 1 |
| Hachulla, E; Humbert, M; Launay, D | 1 |
| Gabbay, E; Reed, A; Williams, TJ | 1 |
| Boyer, L; Chabot, F; Gomez, E; Herve, P; Kheir, A; Le Pavec, J; Sitbon, O | 1 |
| Bevilacqua, M; Brancaccio, G; Di Chiara, L; Parisi, F; Toscano, A | 1 |
| Hoeper, MM | 2 |
| Gaine, SP; O'Callaghan, D; O'Callaghan, DS | 1 |
| Baloira, A | 1 |
| Fink, CA; Johnson, RF; Loyd, JE; Mullican, AL; Robbins, IM | 1 |
| Benza, RL; Girgis, RE; Keogh, A; Park, MH | 1 |
| Häusler, S; Schneiter, R; Stieger, B; Treiber, A | 1 |
| Blanco-Aparicio, M; Ferrer-Barba, A; Medrano-López, C; Otero-González, I; Raposo-Sonnenfeld, I | 1 |
| Boonstra, A; Bronzwaer, JG; Gan, CT; Holverda, S; Marcus, JT; Marques, KM; Paulus, WJ; Postmus, PE; Twisk, JW; Vonk-Noordegraaf, A | 1 |
| Cornel, JH; Duffels, MG; Hamaker, ME; Mulder, BJ; Reichert, CL; Umans, VA | 1 |
| Humbert, M | 1 |
| Iwamoto, M; Kamata, Y; Minota, S | 1 |
| Callejas-Rubio, JL; Ortego-Centeno, N; Ríos-Fernández, R; Tomás, C | 1 |
| Burgess, G; Collings, L; Dingemanse, J; Hoogkamer, H | 1 |
| Almeida, AR; Almeida, S; Carrageta, M; Cordeiro, P; Cotrim, C; Loureiro, MJ; Miranda, R; Simões, O | 1 |
| Fischler, M; Huber, LC; Maggiorini, M; Speich, R; Spring, RM; Treder, U; Ulrich, S | 1 |
| Diaz-Guzman, E; Dweik, RA; Heresi, GA; Minai, OA | 1 |
| Austin, MJ; Callender, ME; Heneghan, MA; Knisely, AS; McDougall, NI; O'Grady, JG; Rela, M; Sizer, E; Wendon, JA; Wilson, C | 1 |
| Park, MH | 1 |
| Antonelli-Incalzi, R; Catapano-Minotti, G; Corsonello, A; Guadalupi, G; Spani, R | 1 |
| Bergstrom, KG; Perelman, RO | 1 |
| Gewitz, M; Krishnan, S; Krishnan, U | 1 |
| Bouros, D; Steiropoulos, P; Trakada, G | 1 |
| Stähler, G | 1 |
| Ewert, R; Gläser, S; Opitz, CF; Schäper, C | 1 |
| Distler, O; Tamborrini, G | 1 |
| Broomé, M; Frenckner, B; Lindström, M; Radell, P | 1 |
| Haworth, SG; Hislop, AA | 1 |
| Ahmad, S; Barnett, CF; Barnett, SD; Bonura, EJ; Girgis, RE; Hassoun, PM; Moller, DR; Nathan, SD; Osei, K; Shlobin, OA; Zaiman, AL | 1 |
| De Wolf, D | 1 |
| Li, D; Matuschak, GM; Nayak, RP | 1 |
| Champion, HC; Girgis, RE; Hassoun, PM; Hummers, LK; Mathai, SC; Wigley, FM; Zaiman, A | 1 |
| Beghetti, M; Galiè, N | 1 |
| Boonstra, A; Jacobs, W; Marcus, JT; Postmus, PE; Vonk-Noordegraaf, A | 1 |
| Ambach, A; Bonnekoh, B; Gollnick, H; Seo, W | 1 |
| Hadi, AM; Mouchaers, KT; Postmus, PE; Schalij, I; van der Laarse, WJ; van Hinsbergh, VW; van Nieuw Amerongen, GP; Versteilen, AM; Vonk-Noordegraaf, A | 1 |
| Doherty, DR; Eipe, N; Lai, L | 1 |
| Drinovec, I; Jazbec, SS; Ledinek, AH; Rot, U | 1 |
| Coghlan, G; Humbert, M; McLaughlin, V; Nash, P; Steen, V | 1 |
| Dranitsaris, G; Mehta, S | 1 |
| Bach, D; Dingemanse, J; Doelberg, M; Galiè, N; Gruenig, E; Meyer, FJ; Michelakis, E; Vachiéry, JL; Vizza, CD | 1 |
| Coles, WA; Gladwin, MT; Kato, GJ; Machado, RF; Minniti, CP; Sachdev, V | 1 |
| Barton, P; Chen, YF; Fry-Smith, A; Gibbs, JS; Hyde, C; Jowett, S; Malottki, K; Moore, D; Pepke-Zaba, J; Roberts, J | 1 |
| Dorfmuller, P; Humbert, M; Jaïs, X; Montani, D; Simonneau, G; Sitbon, O | 1 |
| Achouh, L; Humbert, M; Jais, X; Launay, D; Le Pavec, J; Parent, F; Savale, L; Simonneau, G; Sitbon, O; Tchérakian, C; Yaïci, A | 1 |
| Ross, AF; Ueda, K | 1 |
| Dalton, B; Gabbay, E; Keogh, A; Steele, P; Stewart, S; Strange, G; Wlodarczyk, J | 1 |
| Iversen, K; Jensen, AS; Jensen, TV; Søndergaard, L; Vejlstrup, NG | 1 |
| Humbert, M; Montani, D | 1 |
| Humbert, M; Jais, X; Sanchez, O; Simonneau, G; Sitbon, O | 1 |
| Hunsche, E; Lefebvre, MC | 1 |
| Białkowski, J | 1 |
| de Boer, MA; Mouchaers, KT; Postmus, PE; Schalij, I; van der Laarse, WJ; van Hinsbergh, VW; van Nieuw Amerongen, GP; Vonk Noordegraaf, A | 1 |
| Castel, A; Farrero, M; Perez-Villa, F; Roig, E; Sionis, A | 1 |
| Benza, RL; Channick, RN; McLaughlin, VV; Olschewski, H; Robbins, IM; Rubenfire, M; Rubin, LJ; Seeger, W; Tapson, VF; Voswinckel, R | 1 |
| Du, J; He, B; Jin, H; Li, X; Lin, G; Tang, C; Zhang, F | 1 |
| Cordier, JF; Cottin, V; Etienne-Mastroïanni, B; Humbert, M; Khouatra, C; Kiakouama, L | 1 |
| Angalakuditi, M; Bancroft, T; Beardsworth, A; Buysman, E; Edgell, E | 1 |
| Bilan, VP; Jackson, EK; Jones, TJ; Petrusevska, G; Tofovic, SP | 1 |
| Gocho, K; Homma, S; Kusano, E; Ota, H; Sugino, K; Takai, Y | 1 |
| Argiento, P; Calabrò, R; Correra, A; D'Alto, M; Grimaldi, N; Romeo, E; Russo, MG; Santoro, G; Sarubbi, B; Scognamiglio, G | 1 |
| Brown, K; Dalton, B; Gabbay, E; Keogh, A; Kermeen, F; Kilpatrick, D; Kotlyar, E; Macdonald, P; Pidoux, A; Steele, P; Strange, G; Williams, T | 1 |
| Sitbon, O | 1 |
| Bruni, A; Camerini, P; Radicioni, M | 1 |
| Akita, C; Hashimoto, Y; Hirono, K; Horiuchi, I; Ichida, F; Kato, Y; Miyawaki, T; Nakamura, T; Nakayama, T; Saji, T; Taguchi, M; Yoshimura, N | 1 |
| Davie, N; Hall, SM; Haworth, SG; Klein, N | 1 |
| Bauleo, C; Catapano, G; Formichi, B; Genovesi, D; Giuntini, C; Mannucci, F; Marini, C; Michelassi, C; Monti, S; Prediletto, R | 1 |
| Iwamoto, Y; Kawasaki, H; Senzaki, H; Taketazu, M; Tamai, A | 1 |
| Burtscher, M; Faulhaber, M; Flatz, M; Kleinsasser, A; Loeckinger, A; Olfert, IM; Treml, B; Truebsbach, S | 1 |
| Andrews, JC; Kamath, PS; Krowka, MJ; Swanson, KL; Talwalkar, JA | 1 |
| Andreassen, AK; Gude, E; Solberg, OG; Ueland, T | 1 |
| Hatano, M; Hirata, Y; Kinugawa, K; Nagai, R; Yao, A | 1 |
| Hunzelmann, N; Krieg, T; Moinzadeh, P | 1 |
| Datar, SA; Fineman, JR; Oishi, P | 1 |
| Celermajer, DS; Fowler, D; Garsia, R; Low, AJ; Manghani, MK; Torzillo, P; Young, I; Youssef, P | 1 |
| Benza, RL; Channick, RN; McLaughlin, VV; Olschewski, H; Robbins, IM; Rubin, LJ; Seeger, W; Tapson, VF; Voswinckel, R | 1 |
| Gatzoulis, MA | 1 |
| Aoki, T; Fukumoto, Y; Miura, Y; Miyamichi-Yamamoto, S; Nochioka, K; Satoh, K; Shimokawa, H; Sugimura, K; Tatebe, S | 1 |
| Chin, T; Do, P; Nussbaum, E; Parsapour, K; Randhawa, I | 1 |
| Sirmagul, B; Yigitaslan, S | 1 |
| Allen, RP; Arneson, C; Badesch, DB; Frantz, RP; Frost, AE; Galiè, N; Keogh, AM; Kermeen, F; Laliberte, K; Shapiro, SM; Sigman, J; Tapson, VF; Torres, F | 1 |
| Athanassopoulos, GD; Demerouti, EA; Karatasakis, GT; Leontiadis, ED; Manginas, AN; Pavlides, GS | 1 |
| Catrina, D; Coman, IM; Dima, L; Ghiorghiu, I; Ginghina, C; Giusca, S; Jurcut, R; Popescu, BA | 1 |
| Gerry Coghlan, J; Humbert, M; Khanna, D | 1 |
| D'Alto, M; Mahadevan, VS | 1 |
| Burhenne, J; Haefeli, WE; Riedel, KD; Spalwisz, A; Theile, D; Weiss, J | 1 |
| Boutou, A; Kontou, P; Paspala, A; Pitsiou, G; Sourla, E; Stanopoulos, I | 1 |
| Celermajer, DS; Corte, TJ; Don, GW; Joseph, F | 1 |
| Ishida, F; Ishida, K; Kawakami, T; Kodama, Y; Matsuoka, K; Nakazawa, A; Takemura, T; Tao, K; Tsuchiya, K; Yoda, H | 1 |
| Feinstein, JA; Ivy, DD; Maxey, DM; Ogawa, MT | 1 |
| Catarsi, E; Doveri, M; Tavoni, A | 1 |
| Lee, JS; Lee, SD; Oh, YM; Park, DA; Park, J; Song, JH | 1 |
| Humbert, M; Jardim, C; Souza, R | 1 |
| Cannon, JE; Pepke-Zaba, J | 1 |
| Steinhorn, RH | 1 |
| Deiros, L; Del Cerro, MJ; Gutierrez-Larraya, F; Herrero, A; Roldan, T; Romero, JA | 1 |
| Hoenicka, M; Hofmann, HS; Liebold, A; Neu, R; Potzger, T; Ried, M; Sziklavari, Z; Szöke, T | 1 |
| Hayashi, H; Hirai, K; Itoh, K; Ono, Y; Todoroki, K; Tomatsuri, M; Toyo'oka, T; Yamada, H; Yamada, Y; Yokoyama, Y | 1 |
| Bartelds, B; Berger, RM; Douwes, JM; Hillege, HL; Ploegstra, MJ; Roofthooft, MT; Van Loon, RL | 1 |
| Cingoz, F; Kurkluoglu, M; Sahin, MA; Tavlasoglu, M | 1 |
| Bergot, E; Bouvaist, H; Bulifon, S; Cottin, V; Dauphin, C; Humbert, M; Jaïs, X; Macari, EA; Montani, D; Picard, F; Savale, L; Simonneau, G; Sitbon, O | 1 |
| Adachi, S; Hirashiki, A; Kondo, T; Matsubara, H; Miyaji, K; Murohara, T; Nakaguro, M; Ogawa, A; Yokoi, T | 1 |
| Watanabe, H | 1 |
| Fukumoto, Y | 1 |
| Morrell, NW; Pepke-Zaba, J; Sheares, K; Soon, E; Southwood, M | 1 |
| Cebotari, S; Hoeper, MM; Madani, MM; Meyer, B; Nakanishi, N; Rubin, LJ | 1 |
| Baloira Villar, A; Núñez Fernández, M; Pousada Fernández, G; Valverde Pérez, D | 1 |
| Cleary, KL; Običan, SG | 1 |
| Corkill, MM; Ghosh, SK; Hart, HH; Ng, KP | 1 |
| Güllülü, S; Sağ, S; Yeşilbursa, D | 1 |
| Buyukakilli, B; Citirik, D; Gurgul, S; Hallioglu, O; Ozeren, M; Tasdelen, B | 1 |
| Başer, HD; Cengel, A; Taçoy, G; Türkoğlu, S | 1 |
| Gómez-Meda, BC; Lemus-Varela, Mde L; Melnikov, V; Ornelas-Aguirre, JM; Soliz, A; Torres-Mendoza, BM; Zamora-Perez, AL; Zúñiga-González, GM | 1 |
| Bouillon, T; Flesch, G; Quinn, D; Renard, D; Zhou, P | 1 |
| Bull, DA; Hatton, N; Ryan, JJ; Suksaranjit, P; Wilson, BD | 1 |
| Fujita, J; Fukuda, K; Kataoka, M; Kimura, M; Kuwana, M; Ono, T; Satoh, T; Takei, M; Tamura, Y; Yamamoto, T | 1 |
| Albini, A; Bacchi Reggiani, ML; Bachetti, C; Dardi, F; Galiè, N; Gotti, E; Manes, A; Mazzanti, G; Monti, E; Palazzini, M; Rinaldi, A | 1 |
| Avcu, F; Doganci, S; Erol, G; Kadan, M; Ozgurtas, T; Ozkan, G; Yesildal, F; Yildirim, V | 1 |
| Al Hiti, H; Channick, RN; Ghofrani, HA; Hoeper, MM; Lemarié, JC; McLaughlin, V; Meyer, G; Naeije, R; Packer, M; Souza, R; Tapson, VF; Tolson, J | 1 |
| Rubin, LJ; Vachiery, JL | 1 |
| Chabanne, C; Cordier, JF; Cottin, V; Delaval, P; Girard, A; Jouneau, S; Khouatra, C; Lannes, M; Traclet, J; Turquier, S | 1 |
| Ando, K; Hoshika, Y; Ienaga, H; Kimura, T; Kuraishi, H; Morio, Y; Nagaoka, T; Takahashi, K; Tsutsumi, T | 1 |
| Kornacewicz-Jach, Z; Peregud-Pogorzelska, M | 1 |
| Berger, JT; Grant, EK | 1 |
| Burhenne, J; Enderle, Y; Friedrich, J; Grünig, E; Haefeli, WE; Meid, AD; Wilkens, H | 1 |
| Bellando-Randone, S; Blagojevic, J; Bruni, C; Cometi, L; De Paulis, A; Guiducci, S; Lepri, G; Matucci-Cerinic, M; Radicati, A | 1 |
| Goldberg, DJ; Paridon, SM; Rychik, J; Snarr, BS | 1 |
| Hakamata, A; Inui, N; Irisawa, H; Miyakawa, S; Odagiri, K; Takeuchi, K; Tanaka, S; Uchida, S; Watanabe, H | 1 |
| Fan, R; Fan, Y; Ji, R; Penny, DJ; Varghese, NP; Wang, G; Zou, W | 1 |
| Lejnieks, A; Lesina, K; Rudzitis, A; Sablinskis, K; Skride, A | 1 |
| Etnel, J; Helbing, WA; Mank, A; Oldenburger, NJ; Takkenberg, JJ | 1 |
| Bauer, F; Bergot, E; Bertoletti, L; Bourdin, A; Bouvaist, H; Chabannes, C; Chaouat, A; Cottin, V; Dauphin, C; De Groote, P; Humbert, M; Jaïs, X; Montani, D; Sattler, C; Savale, L; Simonneau, G; Sitbon, O | 1 |
| Birk, E; Bruckheimer, E; Dagan, T; Kadmon, G; Schiller, O; Schonfeld, T | 1 |
| Igarashi, A; Inoue, S; Ishii, T; Tsutani, K; Watanabe, H | 1 |
| Jachowicz, R; Krupa, A; Majda, D; Mozgawa, W; Szlęk, J | 1 |
| Akagi, S; Akagi, T; Ejiri, K; Ito, H; Nakagawa, K; Nakamura, K; Sarashina, T; Takaya, Y | 1 |
| Blaise, S; Cracowski, JL; Forli, A; Imbert, B; Roustit, M | 1 |
| Großer, C; Hoenicka, M; Hofmann, HS; Lang, G; Lehle, K; Neu, R; Ried, M; Szöke, T | 1 |
| Benjamin, N; Burhenne, J; Egenlauf, B; Enderle, Y; Fischer, C; Grünig, E; Haefeli, WE; Harutyunova, S; Huppertz, A; Klose, H; Ohnesorge, J | 1 |
| Luecke, C; McPherson, C | 1 |
| Boehm, C; Celermajer, D; Cordina, R; Corte, T; Garsia, R; Lau, E; Moonen, A; Torzillo, P; Youssef, P | 1 |
| Fontaine, C; Jaquinandi, V; Mahe, G; Omarjee, L | 1 |
| AboElnas, MM; Elshafay, A; Hirayama, K; Huy, NT; Idrees, H; Metwali, HG; Saad, OA; Truong, DH; Vuong, NL | 1 |
| Dombi, T; Jansa, P; Teal, S; Vizza, CD; Zhou, D | 1 |
| Balli, E; Buyukakilli, B; Gurgul, S; Hallioglu, O; Karpuz, D; Ozeren, M; Tasdelen, B | 1 |
| Cancrini, C; D'Argenio, P; Diociaiuti, A; El Hachem, M; Iughetti, L; Onnis, G; Zangari, P | 1 |
| Behr, J; Bonella, F; Costabel, U; Geißler, K; Günther, A; Koschel, D; Kreuter, M; Müller-Quernheim, J; Prasse, A; Schönfeld, N; Sitter, H | 1 |
| Apitz, C; Schranz, D | 1 |
| Alfraidi, H; Bshouty, Z; Qanash, S | 1 |
| Dweik, RA; Heresi, GA; Highland, KB; Love, TE; Tonelli, AR | 1 |
| Baba, T; Iijima, S; Ohishi, A; Ueno, D | 1 |
| Chen, J; Liu, J; Qian, X; Tang, W; Xie, T; You, R; Zeng, F; Zhang, Y | 1 |
| Abignano, G; Allanore, Y; Avouac, J; Bellando-Randone, S; Blagojevic, J; Cometi, L; Czirják, L; Del Galdo, F; Denton, CP; Distler, O; Frerix, M; Guiducci, S; Huscher, D; Jaeger, VK; Lóránd, V; Matucci-Cerinic, M; Maurer, B; Müller-Ladner, U; Nihtyanova, S; Riemekasten, G; Siegert, E; Tarner, IH; Vettori, S; Walker, UA | 1 |
| Abignano, G; Allanore, Y; Avouac, J; Bellando-Randone, S; Blagojevic, J; Bruni, C; Cometi, L; Czirják, L; Del Galdo, F; Denton, CP; Distler, O; Frerix, M; Guiducci, S; Huscher, D; Jaeger, VK; Lóránd, V; Matucci-Cerinic, M; Maurer, B; Moggi-Pignone, A; Müller-Ladner, U; Nihtyanova, S; Riemekasten, G; Siegert, E; Tarner, IH; Vettori, S; Walker, UA | 1 |
| Coons, JC; Kido, K | 1 |
| Sakao, S; Tanabe, N; Tatsumi, K | 1 |
| Kelder, JC; Mager, JJ; Post, MC; Snijder, RJ; Ten Klooster, L; van Thor, MCJ | 1 |
| Geiger, R; Kiechl-Kohlendorfer, U; Michel, M; Podnar, T; Ralser, E; Schermer, E; Stock, K | 1 |
| Amiya, E; Asano, Y; Hatano, M; Komuro, I; Kubota, K; Maki, H; Minatsuki, S; Morita, H; Sato, S; Yoshizaki, A | 1 |
| Sakao, S | 1 |
| Antunes, D; Guimarães, T; Pinto, FJ; Plácido, R; Sousa, I | 1 |
| Idris, N; Jeremiasen, I; Moledina, S; Tran, PK; Tran-Lundmark, K | 1 |
| Abman, SH; Kinsella, JP; Mandell, E | 1 |
| Kam, CW; Ruiz, FE | 1 |
| Shi, J; Song, LL; van den Anker, J; Wu, YE; Yang, XY; Zhang, W; Zhao, W | 1 |
| Gorbachevsky, SV; Shmalts, AA | 1 |
| Chen, C; Chen, J; Chen, T; Chen, Y; Liu, M; Zheng, B; Zheng, H | 1 |
| Amin, F; Kamran, A; Khalid, A; Kumari, V; Patel, N; Rafiq, N; Shaikh, AS; Tebha, SS | 1 |
| Chen, J; Chen, Y; Li, F; Li, J; Luo, J; Luo, P | 1 |
| Mendel, B; Prakoso, R; Setiawan, M; Siagian, SN | 1 |
| Kuno, T; Matsuzaki, Y; Shirasu, T; Sumitomo, N; Takagi, H; Watanabe, A; Watanabe, H; Watanabe, K; Yasuhara, J | 1 |
60 review(s) available for bosentan anhydrous and sildenafil citrate
| Article | Year |
|---|---|
Developments in therapeutics for pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Endothelins; Forecasting; Genetic Therapy; Genotype; Humans; Hypertension, Pulmonary; Mutation; Phosphodiesterase Inhibitors; Piperazines; Polymorphism, Genetic; Purines; Receptors, Transforming Growth Factor beta; Serotonin; Sildenafil Citrate; Sulfonamides; Sulfones; Transcription, Genetic; Vasodilator Agents | 2002 |
Advances in the treatment of secondary pulmonary hypertension.
Topics: Antihypertensive Agents; Bosentan; Cardiac Catheterization; Clinical Trials as Topic; Echocardiography; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Middle Aged; Piperazines; Pulmonary Disease, Chronic Obstructive; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2003 |
[Treatment of pulmonary arterial hypertension in children].
Topics: Antihypertensive Agents; Bosentan; Calcium Channel Blockers; Catheter Ablation; Child; Epoprostenol; Heart Atria; Humans; Hypertension, Pulmonary; Lung Transplantation; Patient Selection; Pediatrics; Piperazines; Purines; Randomized Controlled Trials as Topic; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2004 |
Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease.
Topics: Antihypertensive Agents; Bosentan; Humans; Hypertension, Pulmonary; Piperazines; Pulmonary Disease, Chronic Obstructive; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents; Ventricular Dysfunction, Right | 2005 |
Endothelin antagonism in pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Endothelin-1; Epoprostenol; Humans; Hypertension, Pulmonary; Isoxazoles; Piperazines; Pulmonary Artery; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes | 2005 |
Changing the prognosis of pulmonary arterial hypertension: impact of medical therapy.
Topics: Anticoagulants; Antihypertensive Agents; Bosentan; Calcium Channel Blockers; Clinical Trials as Topic; Epoprostenol; Humans; Hypertension, Pulmonary; Piperazines; Prognosis; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Analysis; Warfarin | 2005 |
Combination drug therapy in the management of pulmonary arterial hypertension.
Topics: Anticoagulants; Antihypertensive Agents; Bosentan; Calcium Channel Blockers; Cardiotonic Agents; Diuretics; Drug Monitoring; Drug Therapy, Combination; Epoprostenol; Humans; Hypertension, Pulmonary; Iloprost; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prostaglandins; Purines; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2005 |
Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Antihypertensive Agents; Bosentan; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Phosphodiesterase Inhibitors; Piperazines; Prostaglandins, Synthetic; Purines; Sildenafil Citrate; Sulfonamides; Sulfones | 2006 |
An evidence-based approach to the management of pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Benzamides; Bosentan; Calcium Channel Blockers; Comorbidity; Dichloroacetic Acid; Drug Therapy, Combination; Epoprostenol; Evidence-Based Medicine; Fluoxetine; Humans; Hypertension, Pulmonary; Iloprost; Imatinib Mesylate; Isoxazoles; Phosphodiesterase Inhibitors; Piperazines; Prostaglandins, Synthetic; Pulmonary Artery; Purines; Pyrimidines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Simvastatin; Sulfonamides; Sulfones; Thiophenes; Vasodilator Agents | 2006 |
The current treatment of pulmonary arterial hypertension: time to redefine success.
Topics: Bosentan; Endothelins; Epoprostenol; Exercise Test; Humans; Hypertension, Pulmonary; Long-Term Care; Phosphodiesterase Inhibitors; Piperazines; Prostaglandins; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome | 2006 |
Pharmacologic treatment for pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Disease Progression; Drug Therapy, Combination; Endothelin-1; Humans; Hypertension, Pulmonary; Phosphodiesterase Inhibitors; Piperazines; Prognosis; Prostaglandins; Pulmonary Artery; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome | 2006 |
Treatment of pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Child; Endothelin Receptor Antagonists; Endothelium-Dependent Relaxing Factors; Epoprostenol; Humans; Hypertension, Pulmonary; Nitric Oxide; Phosphodiesterase Inhibitors; Piperazines; Prognosis; Purines; Receptors, Endothelin; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Sulfones | 2006 |
[Pulmonary arterial hypertension following pulmonary thromboembolism].
Topics: Antihypertensive Agents; Bosentan; Endarterectomy; Humans; Hypertension, Pulmonary; Iloprost; Piperazines; Pulmonary Embolism; Purines; Recurrence; Sildenafil Citrate; Splenectomy; Sulfonamides; Sulfones; Vasodilator Agents | 2006 |
[Drug combination treatment for pulmonary arterial hypertension].
Topics: Administration, Inhalation; Administration, Oral; Antihypertensive Agents; Bosentan; Drug Synergism; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Iloprost; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2006 |
[Pulmonary arterial hypertension and systemic sclerosis].
Topics: Algorithms; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Cohort Studies; Echocardiography, Doppler; Epoprostenol; European Union; Humans; Hypertension, Pulmonary; Iloprost; Infusions, Intravenous; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Prevalence; Prognosis; Purines; Randomized Controlled Trials as Topic; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Time Factors; Vasodilator Agents; World Health Organization | 2006 |
Assessment and treatment of pulmonary arterial hypertension: an Australian perspective in 2006.
Topics: Adolescent; Adult; Aged; Arterioles; Australia; Bosentan; Cardiac Catheterization; Diagnostic Imaging; Disease Progression; Dyspnea; Endothelin A Receptor Antagonists; Epoprostenol; Exercise Test; Female; Forecasting; Heart-Lung Transplantation; Humans; Hypertension, Pulmonary; Iloprost; Lung Transplantation; Male; Middle Aged; Nitric Oxide; Piperazines; Prognosis; Pulmonary Artery; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Vascular Resistance; Vasodilator Agents; Ventricular Dysfunction, Right | 2007 |
[Porto-pulmonary hypertension].
Topics: Antihypertensive Agents; Bosentan; Cardiac Catheterization; Drug Therapy, Combination; Echocardiography; Epoprostenol; Humans; Hypertension, Portal; Hypertension, Pulmonary; Oxygen Inhalation Therapy; Piperazines; Prognosis; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2006 |
Combination therapy and new types of agents for pulmonary arterial hypertension.
Topics: Adrenomedullin; Angiopoietin-1; Antihypertensive Agents; Benzamides; Bosentan; Drug Therapy, Combination; Eicosanoids; Epoprostenol; Genetic Therapy; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Piperazines; Platelet Aggregation Inhibitors; Prostaglandins; Protein Serine-Threonine Kinases; Purines; Pyrimidines; rho-Associated Kinases; Serotonin; Serotonin Plasma Membrane Transport Proteins; Sildenafil Citrate; Sulfonamides; Sulfones; Vasoactive Intestinal Peptide; Vasodilator Agents | 2007 |
Management of pulmonary arterial hypertension with a focus on combination therapies.
Topics: Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Endothelin-1; Epoprostenol; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Male; Piperazines; Pulmonary Artery; Purines; Randomized Controlled Trials as Topic; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Analysis | 2007 |
Advances in diagnosis and treatment in patients with pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Cardiac Catheterization; Disease Progression; Drug Therapy, Combination; Endothelin Receptor Antagonists; Endothelium, Vascular; Epoprostenol; Heart Failure; Humans; Hypertension, Pulmonary; Iloprost; Isoxazoles; Phosphodiesterase Inhibitors; Piperazines; Platelet Aggregation Inhibitors; Prognosis; Pulmonary Artery; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes; Vasoconstriction | 2008 |
Current pharmacological treatment of pulmonary arterial hypertension.
Topics: Bosentan; Diuretics; Epoprostenol; Humans; Hypertension, Pulmonary; Iloprost; Nitric Oxide; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones | 2008 |
[Specific drugs for the treatment of pulmonary arterial hypertension - current status].
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Prostaglandins; Purines; Pyridazines; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Rate; Thiophenes; Vasodilator Agents | 2008 |
[Combination therapy in patients with pulmonary arterial hypertension].
Topics: Administration, Inhalation; Administration, Oral; Antihypertensive Agents; Bosentan; Clinical Trials as Topic; Drug Therapy, Combination; Exercise Test; Hemodynamics; Humans; Hypertension, Pulmonary; Iloprost; Piperazines; Prostaglandins; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2008 |
[Update in pulmonary hypertension associated with connective tissue diseases - a systematic literature review].
Topics: Antihypertensive Agents; Bosentan; Cardiac Catheterization; Connective Tissue Diseases; Drug Therapy, Combination; Echocardiography; Humans; Hypertension, Pulmonary; Magnetic Resonance Imaging; Piperazines; Prevalence; Prognosis; Purines; Respiratory Function Tests; Sensitivity and Specificity; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Rate; Vasodilator Agents | 2008 |
Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Eisenmenger Complex; Endothelin Receptor Antagonists; Epoprostenol; Humans; Hypertension, Pulmonary; Isoxazoles; Phosphodiesterase Inhibitors; Piperazines; Pulmonary Circulation; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes | 2009 |
Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.
Topics: Antihypertensive Agents; Bosentan; Cardiac Catheterization; Echocardiography; Epoprostenol; Exercise Tolerance; Humans; Hypertension, Pulmonary; Piperazines; Purines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones | 2009 |
Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
Topics: Antihypertensive Agents; Bosentan; Cost-Benefit Analysis; Endothelin Receptor Antagonists; Epoprostenol; Humans; Hypertension, Pulmonary; Iloprost; Isoxazoles; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes; United States; Vasodilator Agents | 2009 |
Pulmonary hypertension in thoracic surgical patients.
Topics: Anesthesia, Inhalation; Antihypertensive Agents; Bosentan; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Epoprostenol; Humans; Hypertension, Pulmonary; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Thoracic Surgical Procedures; Vasodilator Agents | 2010 |
Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Cohort Studies; Epoprostenol; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Piperazines; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes; Time Factors; Treatment Outcome | 2010 |
[Guidelines for the diagnosis and treatment of pulmonary hypertension].
Topics: Algorithms; Antihypertensive Agents; Bosentan; Carbolines; Drug Therapy, Combination; Endothelin Receptor Antagonists; Europe; Evidence-Based Medicine; Humans; Hypertension, Pulmonary; Piperazines; Practice Guidelines as Topic; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Vasodilator Agents | 2010 |
Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Drug-Related Side Effects and Adverse Reactions; Humans; Hypertension, Pulmonary; Iloprost; Piperazines; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2010 |
Advances in the management of pediatric pulmonary hypertension.
Topics: Animals; Antihypertensive Agents; Bosentan; Child; Citrulline; Drug Therapy, Combination; Endothelium, Vascular; Hemodynamics; Humans; Hypertension, Pulmonary; Infant; Infant, Newborn; Muscle Contraction; Persistent Fetal Circulation Syndrome; Phosphodiesterase 5 Inhibitors; Piperazines; PPAR gamma; Prostaglandins; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vascular Resistance; Vasoconstriction; Ventricular Function, Right | 2011 |
Successful management of plastic bronchitis in a child post Fontan: case report and literature review.
Topics: Antihypertensive Agents; Bosentan; Bronchitis; Bronchoscopy; Child; Combined Modality Therapy; Drug Therapy, Combination; Expectorants; Female; Fontan Procedure; Heart Defects, Congenital; Humans; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Tissue Plasminogen Activator; Treatment Outcome; Vasodilator Agents | 2012 |
Successful epoprostenol withdrawal in pulmonary arterial hypertension: case report and literature review.
Topics: Acenocoumarol; Anticoagulants; Antihypertensive Agents; Bosentan; Epoprostenol; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Middle Aged; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents; Withholding Treatment | 2013 |
Early detection and management of pulmonary arterial hypertension.
Topics: Anemia, Sickle Cell; Antihypertensive Agents; Bosentan; Early Diagnosis; Echocardiography, Doppler; Exercise Test; Humans; Hypertension, Pulmonary; Mass Screening; Natriuretic Peptide, Brain; Peptide Fragments; Piperazines; Practice Guidelines as Topic; Purines; Respiratory Function Tests; Risk Factors; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2012 |
Pulmonary arterial hypertension associated with congenital heart disease.
Topics: Antihypertensive Agents; Bosentan; Clinical Trials as Topic; Comorbidity; Down Syndrome; Eisenmenger Complex; Endothelium, Vascular; Epoprostenol; Health Behavior; Heart Defects, Congenital; Heart Transplantation; Humans; Hypertension, Pulmonary; Lung Transplantation; Oxygen Inhalation Therapy; Phosphodiesterase 5 Inhibitors; Piperazines; Practice Guidelines as Topic; Pulmonary Circulation; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Thrombosis | 2012 |
Systematic review and meta-analysis of pulmonary hypertension specific therapy for exercise capacity in chronic obstructive pulmonary disease.
Topics: Antihypertensive Agents; Bosentan; Clinical Trials as Topic; Databases, Factual; Epoprostenol; Humans; Hypertension, Pulmonary; Hypoxia; Piperazines; Pulmonary Disease, Chronic Obstructive; Purines; Risk Factors; Sildenafil Citrate; Sulfonamides; Sulfones; Surveys and Questionnaires | 2013 |
Is distal chronic thromboembolic pulmonary hypertension treatable with PAH targeted drugs?
Topics: Antihypertensive Agents; Bosentan; Chronic Disease; Compassionate Use Trials; Endarterectomy; Humans; Hypertension, Pulmonary; Piperazines; Pulmonary Embolism; Purines; Pyrazoles; Pyrimidines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome | 2013 |
[Pharmacological treatment of pulmonary hypertension at a turning point].
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Carbolines; Endothelin Receptor Antagonists; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Male; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Piperazines; Pulmonary Artery; Purines; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Vascular Resistance; Vasodilator Agents | 2014 |
[Role of the Rho-kinase pathway in pulmonary arterial hypertension].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Bosentan; Drug Therapy, Combination; Epoprostenol; Humans; Hypertension, Pulmonary; Mice; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Purines; Rats; rho-Associated Kinases; Signal Transduction; Sildenafil Citrate; Sulfonamides; Sulfones; Vascular Resistance | 2014 |
Chronic thromboembolic pulmonary hypertension.
Topics: Angioplasty, Balloon; Bosentan; Chronic Disease; Endarterectomy; Endothelin Receptor Antagonists; Enzyme Activators; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Piperazines; Pulmonary Embolism; Purines; Pyrazoles; Pyrimidines; Sildenafil Citrate; Sulfonamides; Thromboembolism | 2014 |
Pulmonary arterial hypertension in pregnancy.
Topics: Anesthesia, Obstetrical; Bosentan; Carbolines; Directive Counseling; Epoprostenol; Extracorporeal Membrane Oxygenation; Familial Primary Pulmonary Hypertension; Female; Humans; Iloprost; Infant, Newborn; Piperazines; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Outcome; Pregnancy, High-Risk; Prognosis; Pulmonary Circulation; Purines; Sildenafil Citrate; Sulfonamides; Tadalafil | 2014 |
[Pregnant woman with pulmonary hypertension].
Topics: Antihypertensive Agents; Bosentan; Female; Humans; Hypertension, Pulmonary; Iloprost; Phosphodiesterase Inhibitors; Pregnancy; Pregnancy Complications; Sildenafil Citrate; Sulfonamides | 2015 |
Pulmonary vasodilator therapy in the failing Fontan circulation: rationale and efficacy.
Topics: Bosentan; Cardiac Output; Endothelin Receptor Antagonists; Fontan Procedure; Heart Defects, Congenital; Heart Failure; Humans; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Postoperative Complications; Pulmonary Circulation; Pyridazines; Sildenafil Citrate; Sulfonamides; Vascular Resistance; Vasodilator Agents | 2015 |
Drug therapy in the prevention of failure of the Fontan circulation: a systematic review.
Topics: Bosentan; Endothelin Receptor Antagonists; Exercise Test; Exercise Tolerance; Fontan Procedure; Heart Defects, Congenital; Hemodynamics; Humans; Iloprost; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Treatment Outcome; Vasodilator Agents | 2016 |
Comparative Effectiveness of Oral Medications for Pulmonary Arterial Hypertension.
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Treatment Outcome; Vasodilator Agents | 2016 |
Treatment of Persistent Pulmonary Hypertension of the Newborn: Use of Pulmonary Vasodilators in Term Neonates.
Topics: Bosentan; Humans; Infant, Newborn; Milrinone; Nitric Oxide; Oxygen Inhalation Therapy; Persistent Fetal Circulation Syndrome; Prostaglandins; Sildenafil Citrate; Sulfonamides; Treatment Outcome; Vasodilator Agents | 2017 |
The Effect of Endothelin Receptor Antagonists in Patients with Eisenmenger Syndrome: A Systematic Review.
Topics: Antihypertensive Agents; Blood Pressure; Bosentan; Clinical Trials as Topic; Eisenmenger Complex; Endothelin Receptor Antagonists; Humans; Quality of Life; Sildenafil Citrate; Sulfonamides; Vasodilator Agents | 2018 |
Hypertrophic pyloric stenosis following persistent pulmonary hypertension of the newborn: a case report and literature review.
Topics: Antihypertensive Agents; Atropine; Bosentan; Bronchodilator Agents; Female; High-Frequency Ventilation; Humans; Infant, Newborn; Meconium Aspiration Syndrome; Muscarinic Antagonists; Nitric Oxide; Nitric Oxide Donors; Nitroglycerin; Persistent Fetal Circulation Syndrome; Pyloric Stenosis, Hypertrophic; Sildenafil Citrate; Vasodilator Agents | 2018 |
Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review.
Topics: Antihypertensive Agents; Bosentan; Cost-Benefit Analysis; Endothelin Receptor Antagonists; Epoprostenol; Humans; Hypertension, Pulmonary; Phenylpropionates; Pyridazines; Sildenafil Citrate; Vasodilator Agents | 2018 |
Efficacy and Safety of the Use of Pulmonary Arterial Hypertension Pharmacotherapy in Patients with Pulmonary Hypertension Secondary to Left Heart Disease: A Systematic Review.
Topics: Bosentan; Endothelin Receptor Antagonists; Heart Diseases; Hemodynamics; Humans; Pulmonary Arterial Hypertension; Pyrazoles; Pyrimidines; Sildenafil Citrate; Sulfonamides | 2019 |
Hypoxic Pulmonary Vasoconstriction and the Diffusing Capacity in Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis.
Topics: Bosentan; Disease Progression; Endothelin Receptor Antagonists; Enzyme Activators; Humans; Hypertension, Pulmonary; Hypoxia; Idiopathic Pulmonary Fibrosis; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Circulation; Pulmonary Diffusing Capacity; Pulmonary Ventilation; Pyrazoles; Pyrimidines; Sildenafil Citrate; Treatment Failure; Vascular Remodeling; Vasoconstriction | 2019 |
Persistent pulmonary hypertension of the newborn.
Topics: Bosentan; Epoprostenol; Humans; Hypertension, Pulmonary; Hypoxia; Infant; Infant, Newborn; Infant, Premature; Lung; Milrinone; Nitric Oxide; Oxygen; Persistent Fetal Circulation Syndrome; Pulmonary Alveoli; Pulmonary Surfactants; Risk; Sildenafil Citrate; Vascular Resistance; Vasodilator Agents | 2021 |
Opportunities and challenges of pharmacotherapy for pulmonary arterial hypertension in children.
Topics: Adolescent; Adult; Bosentan; Calcium Channel Blockers; Child; Child, Preschool; Epoprostenol; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Iloprost; Infant; Infant, Newborn; Phenotype; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Prognosis; Pulmonary Arterial Hypertension; Pyridazines; Pyrimidines; Receptors, Endothelin; Sildenafil Citrate; Sulfonamides; Tadalafil; Young Adult | 2021 |
Oral drugs used to treat persistent pulmonary hypertension of the newborn.
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Humans; Infant, Newborn; Off-Label Use; Persistent Fetal Circulation Syndrome; Randomized Controlled Trials as Topic; Sildenafil Citrate; Tadalafil | 2020 |
[Advantages and limitations of initial combination therapy in pulmonary arterial hypertension patients in Russia].
Topics: Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Pulmonary Arterial Hypertension; Russia; Sildenafil Citrate | 2020 |
Systematic review and cost-effectiveness of bosentan and sildenafil as therapeutic drugs for pediatric pulmonary arterial hypertension.
Topics: Bosentan; Child; Cost-Benefit Analysis; Humans; Hypertension, Pulmonary; Pharmaceutical Preparations; Pulmonary Arterial Hypertension; Quality of Life; Sildenafil Citrate | 2021 |
Comparative Efficacy and Safety of Targeted Therapies for Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review and Network Meta-Analysis.
Topics: Antihypertensive Agents; Bosentan; Humans; Hypertension, Pulmonary; Natriuretic Peptide, Brain; Network Meta-Analysis; Sildenafil Citrate; Treatment Outcome; Vasodilator Agents | 2021 |
Pharmacology Management in Improving Exercise Capacity of Patients with Fontan Circulation: A Systematic Review and Meta-analysis.
Topics: Bosentan; Exercise Test; Exercise Tolerance; Fontan Procedure; Heart Defects, Congenital; Humans; Quality of Life; Sildenafil Citrate; Sulfonamides; Treatment Outcome | 2022 |
Pulmonary vasodilator therapies in pulmonary arterial hypertension associated with CHD: a systematic review and network meta-analysis.
Topics: Antihypertensive Agents; Bosentan; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Network Meta-Analysis; Pulmonary Arterial Hypertension; Sildenafil Citrate; Sulfonamides; Treatment Outcome; Vasodilator Agents | 2023 |
23 trial(s) available for bosentan anhydrous and sildenafil citrate
| Article | Year |
|---|---|
Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study.
Topics: Adult; Antihypertensive Agents; Bosentan; Double-Blind Method; Endothelin Receptor Antagonists; Exercise Tolerance; Female; Heart Ventricles; Humans; Hypertension, Pulmonary; Male; Middle Aged; Natriuretic Peptide, Brain; Organ Size; Phosphodiesterase Inhibitors; Piperazines; Purines; Quality of Life; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome | 2005 |
Goal-oriented treatment and combination therapy for pulmonary arterial hypertension.
Topics: Administration, Inhalation; Algorithms; Antihypertensive Agents; Bosentan; Decision Support Systems, Clinical; Drug Administration Schedule; Drug Therapy, Combination; Female; Germany; Humans; Hypertension, Pulmonary; Iloprost; Lung Transplantation; Male; Middle Aged; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Analysis; Survival Rate; Treatment Outcome | 2005 |
Right ventricular diastolic dysfunction and the acute effects of sildenafil in pulmonary hypertension patients.
Topics: Adult; Antihypertensive Agents; Blood Circulation; Blood Pressure; Bosentan; Epoprostenol; Female; Heart Ventricles; Humans; Hypertension, Pulmonary; Magnetic Resonance Imaging; Male; Middle Aged; Nitric Oxide; Piperazines; Purines; Severity of Illness Index; Sildenafil Citrate; Stroke Volume; Sulfonamides; Sulfones; Vascular Resistance; Vasodilator Agents; Ventricular Dysfunction, Right | 2007 |
Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil.
Topics: Adolescent; Adult; Antihypertensive Agents; Area Under Curve; Bosentan; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Male; Phosphodiesterase Inhibitors; Piperazines; Pulmonary Artery; Purines; Sildenafil Citrate; Sulfonamides; Sulfones | 2008 |
Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study.
Topics: Antihypertensive Agents; Bosentan; Drug Interactions; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Models, Cardiovascular; Nitric Oxide; Piperazines; Pulmonary Artery; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2009 |
Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Drug Administration Schedule; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Epidemiologic Methods; Epoprostenol; Exercise Test; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Iloprost; Male; Middle Aged; Piperazines; Purines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome | 2010 |
Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Eisenmenger Complex; Female; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Young Adult | 2010 |
Therapy with sildenafil or bosentan decreases pulmonary vascular resistance in patients ineligible for heart transplantation because of severe pulmonary hypertension.
Topics: Administration, Oral; Antihypertensive Agents; Blood Pressure; Bosentan; Contraindications; Heart Failure; Heart Transplantation; Humans; Hypertension, Pulmonary; Piperazines; Prospective Studies; Purines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Sulfones; Vascular Resistance; Vasodilator Agents | 2010 |
Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
Topics: Administration, Inhalation; Administration, Oral; Adult; Aged; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Epoprostenol; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Piperazines; Purines; Quality of Life; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents; Young Adult | 2010 |
Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology.
Topics: Administration, Oral; Adult; Bosentan; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eisenmenger Complex; Exercise Test; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Male; Piperazines; Prospective Studies; Pulmonary Wedge Pressure; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Time Factors; Treatment Outcome; Vascular Resistance | 2012 |
Sildenafil and bosentan improve arterial oxygenation during acute hypoxic exercise: a controlled laboratory trial.
Topics: Adult; Altitude; Bosentan; Cardiac Output; Exercise; Female; Humans; Hypoxia; Male; Mountaineering; Oxygen; Piperazines; Pulmonary Gas Exchange; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2011 |
Acute effect of sildenafil is maintained in pulmonary arterial hypertension patients chronically treated with bosentan.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Piperazines; Prospective Studies; Pulmonary Artery; Pulmonary Wedge Pressure; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vascular Resistance; Young Adult | 2011 |
Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Bosentan; Double-Blind Method; Drug Therapy, Combination; Epoprostenol; Female; Headache; Humans; Hypertension, Pulmonary; Incidence; Longitudinal Studies; Male; Middle Aged; Nausea; Physical Endurance; Piperazines; Purines; Quality of Life; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Young Adult | 2011 |
Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension.
Topics: Aged; Angioplasty; Antihypertensive Agents; Bosentan; Chronic Disease; Combined Modality Therapy; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Piperazines; Prognosis; Prospective Studies; Pulmonary Circulation; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2012 |
Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endothelin Receptor Antagonists; Epoprostenol; Exercise Tolerance; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Walking; Young Adult | 2012 |
Right ventricular function predicts clinical response to specific vasodilator therapy in patients with pulmonary hypertension.
Topics: Adult; Bosentan; Echocardiography; Female; Humans; Hypertension, Pulmonary; Male; Piperazines; Purines; Reproducibility of Results; Sensitivity and Specificity; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents; Ventricular Dysfunction, Right; Ventricular Function, Right | 2013 |
Pharmacokinetic interactions among imatinib, bosentan and sildenafil, and their clinical implications in severe pulmonary arterial hypertension.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Bosentan; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Male; Sildenafil Citrate; Sulfonamides; Vascular Resistance; Young Adult | 2015 |
Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prospective Studies; Sildenafil Citrate; Sulfonamides; Switzerland; Treatment Outcome; Vasodilator Agents | 2015 |
Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil-Bosentan and Sildenafil-Ambrisentan Combination Therapies for Pulmonary Hypertension.
Topics: Adult; Bosentan; Drug Therapy, Combination; Exercise; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phenylpropionates; Pyridazines; Sildenafil Citrate; Sulfonamides | 2016 |
Feasibility of Repairing Defects Followed by Treatment with Pulmonary Hypertension-specific Drugs (Repair and Treat) in Patients with Pulmonary Hypertension Associated with Atrial Septal Defect: Study Protocol for Interventional Trial.
Topics: Antihypertensive Agents; Bosentan; Clinical Protocols; Drug Administration Schedule; Feasibility Studies; Heart Septal Defects, Atrial; Humans; Hypertension, Pulmonary; Prospective Studies; Sildenafil Citrate; Sulfonamides | 2016 |
Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.
Topics: Adult; Aged; Antihypertensive Agents; Arterial Pressure; Bosentan; Double-Blind Method; Drug Therapy, Combination; Endothelin Receptor Antagonists; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Least-Squares Analysis; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Pulmonary Artery; Recovery of Function; Sildenafil Citrate; Sulfonamides; Time Factors; Treatment Outcome; Vasodilator Agents; Walk Test | 2017 |
Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey.
Topics: Adult; Bosentan; Calcium Channel Blockers; Drug Therapy, Combination; European Union; Female; Fingers; Humans; Iloprost; Male; Middle Aged; Prospective Studies; Scleroderma, Systemic; Sildenafil Citrate; Skin Ulcer; Surveys and Questionnaires | 2019 |
Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study.
Topics: Adult; Aged; Bosentan; Drug Therapy, Combination; Europe; Female; Fingers; Humans; Iloprost; Male; Middle Aged; Prospective Studies; Scleroderma, Systemic; Sildenafil Citrate; Skin Ulcer; Treatment Outcome; Vasodilator Agents; Wound Healing | 2020 |
124 other study(ies) available for bosentan anhydrous and sildenafil citrate
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension.
Topics: Adult; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Male; Pilot Projects; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2004 |
Combination of sildenafil and bosentan for nitric oxide withdrawal.
Topics: Antihypertensive Agents; Bosentan; Extracorporeal Membrane Oxygenation; Female; Humans; Middle Aged; Nitric Oxide; Phosphodiesterase Inhibitors; Piperazines; Purines; Respiratory Distress Syndrome; Sildenafil Citrate; Substance Withdrawal Syndrome; Sulfonamides; Sulfones; Vasodilator Agents; Ventilator Weaning | 2005 |
Eisenmenger's syndrome in a 27 week pregnancy--management with bosentan and sildenafil.
Topics: Adult; Antihypertensive Agents; Bosentan; Cesarean Section; Eisenmenger Complex; Female; Humans; Piperazines; Postoperative Care; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Outcome; Prenatal Care; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2005 |
Pulmonary arterial hypertension: the race for the most effective treatment.
Topics: Antihypertensive Agents; Bosentan; Drug Evaluation; Endothelin Receptor Antagonists; Epoprostenol; Humans; Hypertension, Pulmonary; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome | 2005 |
Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Area Under Curve; Bosentan; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones | 2005 |
Combination therapy with bosentan and phosphodiesterase-5 inhibitor in pulmonary arterial hypertension.
Topics: Adult; Bosentan; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Humans; Hypertension, Pulmonary; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Risk Assessment; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome | 2005 |
[A role for combination therapy in pulmonary arterial hypertension].
Topics: Administration, Inhalation; Antihypertensive Agents; Bosentan; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Iloprost; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones | 2005 |
Successful switch from long-term intravenous iloprost to non-invasive combination therapy in idiopathic pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Drug Administration Schedule; Drug Combinations; Female; Humans; Hypertension, Pulmonary; Iloprost; Injections, Intravenous; Middle Aged; Patient Selection; Piperazines; Pulmonary Artery; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2006 |
Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats.
Topics: Animals; Bosentan; Disease Models, Animal; Drug Therapy, Combination; Endothelin Receptor Antagonists; Hypertension, Pulmonary; Male; Monocrotaline; Phosphodiesterase Inhibitors; Piperazines; Purines; Rats; Rats, Wistar; Sildenafil Citrate; Sulfonamides; Sulfones | 2006 |
An evidence-based approach to the management of pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Disease Management; Drug Interactions; Endothelin Receptor Antagonists; Evidence-Based Medicine; Humans; Hypertension, Pulmonary; Isoxazoles; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes; Vasodilator Agents; Walking | 2006 |
First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.
Topics: Administration, Oral; Adolescent; Adult; Antihypertensive Agents; Bosentan; Child; Child, Preschool; Drug Therapy, Combination; Endothelin Receptor Antagonists; Exercise Test; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Prospective Studies; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome | 2006 |
Long-term results after addition of sildenafil in idiopathic PAH patients on bosentan.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Pulmonary Wedge Pressure; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Time Factors | 2006 |
Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Drug Therapy, Combination; Exercise Test; Female; Humans; Hypertension, Pulmonary; Lung Volume Measurements; Male; Middle Aged; Piperazines; Pulmonary Wedge Pressure; Purines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2007 |
Combination therapy with sildenafil and bosentan reverts severe pulmonary hypertension and allows heart transplantation: case report.
Topics: Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Heart Transplantation; Humans; Hypertension, Pulmonary; Male; Middle Aged; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents; Waiting Lists | 2006 |
[Systemic sclerosis: paths into the future].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Forecasting; Humans; Phosphodiesterase Inhibitors; Piperazines; Prognosis; Prostaglandins I; Purines; Quality of Life; Research; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2006 |
Bosentan and sildenafil: should the combination therapy be a valid alternative in childhood to prostacyclin infusion?
Topics: Antihypertensive Agents; Bosentan; Child; Drug Therapy, Combination; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Lung Transplantation; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2007 |
Observational trials in pulmonary arterial hypertension: low scientific evidence but high clinical value.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Antihypertensive Agents; Bosentan; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Piperazines; Purines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2007 |
[Pulmonary hypertension treatment: future prospects].
Topics: Administration, Intranasal; Administration, Oral; Animals; Bosentan; Drug Evaluation, Preclinical; Endothelin A Receptor Antagonists; Epoprostenol; Forecasting; Humans; Hypertension, Pulmonary; Iloprost; Infusions, Intravenous; Isoxazoles; Life Expectancy; Lung Transplantation; Monocrotaline; Piperazines; Platelet-Derived Growth Factor; Purines; Randomized Controlled Trials as Topic; Rats; Sheep; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes; Vasodilator Agents | 2007 |
Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
Topics: Administration, Inhalation; Administration, Oral; Adult; Aged; Antihypertensive Agents; Blood Pressure; Bosentan; Cardiac Catheterization; Epoprostenol; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Iloprost; Injections, Intravenous; Male; Middle Aged; Piperazines; Purines; Retreatment; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Sulfones; Vascular Resistance; Vasodilator Agents | 2007 |
Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Biological Transport; Bosentan; CHO Cells; Cricetinae; Cricetulus; Cyclosporine; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dehydroepiandrosterone Sulfate; Drug Interactions; Enzyme Inhibitors; Estradiol; Estrone; Humans; Liver-Specific Organic Anion Transporter 1; Molecular Structure; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Piperazines; Purines; Pyrimidines; Rifampin; Sildenafil Citrate; Solute Carrier Organic Anion Transporter Family Member 1B3; Sulfonamides; Sulfones; Warfarin | 2007 |
[Treatment with sildenafil, bosentan, or both in children and young people with idiopathic pulmonary arterial hypertension and Eisenmenger's syndrome].
Topics: Adolescent; Adult; Antihypertensive Agents; Bosentan; Child; Eisenmenger Complex; Female; Humans; Hypertension, Pulmonary; Infant; Male; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2007 |
[Two patients with Eisenmenger syndrome treated with novel agents that target vasodilation of the pulmonary capillary bed].
Topics: Bosentan; Diuretics; Eisenmenger Complex; Female; Humans; Middle Aged; Oxygen Inhalation Therapy; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilation; Vasodilator Agents | 2007 |
[The treatment of idiopathic pulmonary artery hypertension and its relation to systemic scleroderma].
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Epoprostenol; Humans; Hypertension, Pulmonary; Iloprost; Injections, Intravenous; Phosphodiesterase Inhibitors; Piperazines; Purines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2007 |
Consecutive use of sildenafil and bosentan for the treatment of pulmonary arterial hypertension associated with collagen vascular disease: sildenafil as reliever and bosentan as controller.
Topics: Adult; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Lupus Erythematosus, Systemic; Mixed Connective Tissue Disease; Natriuretic Peptide, Brain; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2007 |
[Bosentan and chronic thromboembolic pulmonary hypertension].
Topics: Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Follow-Up Studies; Humans; Hypertension, Pulmonary; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2007 |
Should right ventricle dilatation during exercise have clinical implications in patients with chronic thromboembolic pulmonary hypertension? Case report.
Topics: Adult; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Dilatation, Pathologic; Echocardiography, Doppler; Exercise Test; Female; Humans; Hypertension, Pulmonary; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Thromboembolism; Vascular Resistance; Vasodilator Agents; Ventricular Dysfunction, Right | 2007 |
Sildenafil for pulmonary hypertension: dose-dependent improvement in exercise performance.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Bosentan; Dose-Response Relationship, Drug; Exercise; Female; Heart Rate; Humans; Hypertension, Pulmonary; Male; Middle Aged; Oxygen Consumption; Phosphodiesterase Inhibitors; Piperazines; Purines; Quality of Life; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents; Walking | 2008 |
Long-term experience after transition from parenteral prostanoids to oral agents in patients with pulmonary hypertension.
Topics: Administration, Oral; Adult; Aged; Antihypertensive Agents; Bosentan; Chi-Square Distribution; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Infusions, Parenteral; Male; Middle Aged; Piperazines; Prostaglandins; Purines; Retrospective Studies; Sildenafil Citrate; Statistics, Nonparametric; Sulfonamides; Sulfones; Treatment Outcome | 2008 |
Safety and efficacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension.
Topics: Adult; Blood Pressure; Bosentan; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Humans; Hypertension, Portal; Hypertension, Pulmonary; Iloprost; Liver Diseases; Liver Transplantation; Male; Piperazines; Pulmonary Artery; Purines; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2008 |
Treatment of severe pulmonary hypertension secondary to scleroderma: a three-drug approach.
Topics: Bosentan; Drug Therapy, Combination; Electrocardiography; Female; Humans; Hypertension, Pulmonary; Iloprost; Middle Aged; Piperazines; Purines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2008 |
Treatment for Raynaud's: beyond calcium channel blockers.
Topics: Arginine; Bosentan; Botulinum Toxins; Calcium Channel Blockers; Humans; Piperazines; Prazosin; Purines; Raynaud Disease; Sildenafil Citrate; Sulfonamides; Sulfones | 2008 |
Treatment of pulmonary hypertension in children with chronic lung disease with newer oral therapies.
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Bronchopulmonary Dysplasia; Cardiac Catheterization; Child; Child, Preschool; Chronic Disease; Female; Humans; Hypertension, Pulmonary; Infant; Infant, Newborn; Male; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2008 |
Platelet-derived growth factor inhibition--a new treatment of pulmonary hypertension in congenital diaphragmatic hernia?
Topics: Benzamides; Bosentan; Combined Modality Therapy; Continuous Positive Airway Pressure; Diuretics; Enteral Nutrition; Extracorporeal Membrane Oxygenation; Heart Failure; Hernia, Diaphragmatic; Hernias, Diaphragmatic, Congenital; Humans; Hypertension, Pulmonary; Hypoxia; Iloprost; Imatinib Mesylate; Infant, Newborn; Male; Nitric Oxide; Piperazines; Protein Kinase Inhibitors; Purines; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Sildenafil Citrate; Sulfonamides; Sulfones | 2008 |
Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006.
Topics: Adolescent; Bosentan; Case-Control Studies; Child; Child, Preschool; Epoprostenol; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Infant; Kaplan-Meier Estimate; Lung Transplantation; Male; Nifedipine; Piperazines; Purines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Rate; United Kingdom; Vasodilator Agents | 2009 |
Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience.
Topics: Administration, Inhalation; Administration, Oral; Aged; Antihypertensive Agents; Bosentan; Cohort Studies; Drug Therapy, Combination; Epoprostenol; Female; Follow-Up Studies; Hemodynamics; Humans; Hypertension, Pulmonary; Iloprost; Kaplan-Meier Estimate; Linear Models; Male; Middle Aged; Piperazines; Probability; Purines; Respiratory Function Tests; Retrospective Studies; Risk Assessment; Sarcoidosis; Severity of Illness Index; Sildenafil Citrate; Statistics, Nonparametric; Sulfonamides; Sulfones; Survival Rate; Treatment Outcome | 2009 |
Clinical practice: pulmonary hypertension in children.
Topics: Activin Receptors, Type II; Antigens, CD; Antihypertensive Agents; Bone Morphogenetic Protein Receptors, Type II; Bosentan; Calcium Channel Blockers; Child; Electrocardiography; Endoglin; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Incidence; Piperazines; Point Mutation; Prevalence; Purines; Receptors, Cell Surface; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2009 |
Portopulmonary hypertension.
Topics: Antihypertensive Agents; Bosentan; Cardiac Catheterization; Echocardiography; Epoprostenol; Humans; Hypertension, Portal; Hypertension, Pulmonary; Iloprost; Liver Transplantation; Piperazines; Prognosis; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2009 |
Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.
Topics: Bosentan; Cohort Studies; Comorbidity; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Isoxazoles; Lung Diseases, Interstitial; Male; Maryland; Middle Aged; Piperazines; Prognosis; Proportional Hazards Models; Purines; Receptors, Endothelin; Scleroderma, Diffuse; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Rate; Thiophenes; Vasodilator Agents | 2009 |
Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Male; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2009 |
Low-dose combination therapy of severe digital ulcers in diffuse progressive systemic sclerosis with the endothelin-1 receptor antagonist bosentan and the phosphodiesterase V inhibitor sildenafil.
Topics: Aged; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Fingers; Hand Dermatoses; Humans; Phosphodiesterase Inhibitors; Piperazines; Purines; Scleroderma, Diffuse; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Ulcer | 2009 |
Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension.
Topics: Animals; Body Weight; Bosentan; Capillaries; Cyclic GMP-Dependent Protein Kinases; Diffusion; Endothelin Receptor Antagonists; Fibrosis; Hemodynamics; Hypertension, Pulmonary; In Vitro Techniques; Male; Mitochondria, Heart; Myocardial Contraction; Myocardium; Myocytes, Cardiac; Myoglobin; Organ Size; Oxygen Consumption; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Pulmonary Artery; Purines; Rats; Rats, Wistar; Sildenafil Citrate; Sulfonamides; Sulfones; Ultrasonography | 2009 |
Severe pulmonary hypertension and adenotonsillectomy in a child with Trisomy-21 and obstructive sleep apnea.
Topics: Adenoidectomy; Anesthetics, Intravenous; Anticoagulants; Antihypertensive Agents; Bosentan; Child; Down Syndrome; Elective Surgical Procedures; Epoprostenol; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Intubation, Intratracheal; Piperazines; Piperidines; Propofol; Purines; Remifentanil; Severity of Illness Index; Sildenafil Citrate; Sleep Apnea, Obstructive; Sulfonamides; Sulfones; Tonsillectomy; Treatment Outcome; Vasodilator Agents; Warfarin | 2009 |
Pulmonary arterial hypertension associated with interferon beta treatment for multiple sclerosis: a case report.
Topics: Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Immunologic Factors; Interferon beta-1b; Interferon-beta; Multiple Sclerosis; Piperazines; Pulmonary Artery; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Young Adult | 2009 |
Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Canada; Costs and Cost Analysis; Drug Costs; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Piperazines; Placebos; Purines; Pyridazines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes; Treatment Outcome | 2009 |
Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Drug Evaluation; Drug Therapy, Combination; Endothelin Receptor Antagonists; Exercise Test; Humans; Hypertension, Pulmonary; Middle Aged; Phenylpropionates; Piperazines; Purines; Pyridazines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome | 2009 |
Goal-oriented therapy in pulmonary veno-occlusive disease: a word of caution.
Topics: Bosentan; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Middle Aged; Piperazines; Pulmonary Edema; Pulmonary Medicine; Pulmonary Veno-Occlusive Disease; Purines; Risk; Sildenafil Citrate; Sulfonamides; Sulfones; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
[Endothelin receptor antagonists in the new European guidelines on pulmonary hypertension].
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Europe; Evidence-Based Medicine; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Practice Guidelines as Topic; Purines; Pyridazines; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes | 2010 |
Oral Therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Canada; Cost Control; Drug Costs; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Piperazines; Purines; Pyridazines; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes | 2010 |
[Bosenten and sildenafil in the treatment of Eisenmenger syndrome].
Topics: Adolescent; Antihypertensive Agents; Bosentan; Child; Eisenmenger Complex; Endothelin A Receptor Antagonists; Exercise Test; Humans; Hypertension; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones | 2010 |
Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Oral; Animals; Antihypertensive Agents; Blood Pressure; Bosentan; Familial Primary Pulmonary Hypertension; Heart Ventricles; Hemodynamics; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Monocrotaline; Piperazines; Pulmonary Artery; Purines; Rats; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2010 |
Severe pulmonary hypertension in histiocytosis X: long-term improvement with bosentan.
Topics: Antihypertensive Agents; Bosentan; Dyspnea; Hemodynamics; Histiocytosis, Langerhans-Cell; Humans; Hypertension, Pulmonary; Male; Middle Aged; Piperazines; Purines; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Sulfones | 2010 |
Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States.
Topics: Antihypertensive Agents; Bosentan; Female; Health Care Costs; Health Expenditures; Health Services; Humans; Hypertension, Pulmonary; Insurance Claim Review; Male; Managed Care Programs; Middle Aged; Piperazines; Purines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Sulfones; United States; Vasodilator Agents | 2010 |
Synergistic therapeutic effects of 2-methoxyestradiol with either sildenafil or bosentan on amelioration of monocrotaline-induced pulmonary hypertension and vascular remodeling.
Topics: 2-Methoxyestradiol; Animals; Antihypertensive Agents; Bosentan; Drug Synergism; Drug Therapy, Combination; Estradiol; Female; Hypertension, Pulmonary; Male; Monocrotaline; Muscle, Smooth, Vascular; Piperazines; Pulmonary Artery; Purines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2010 |
[Efficacy of combination therapy with bosentan and sildenafil for refractory pulmonary arterial hypertension associated with fibrotic lung in systemic sclerosis].
Topics: Antihypertensive Agents; Bosentan; Female; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Middle Aged; Piperazines; Purines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2010 |
Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report.
Topics: Adult; Aged; Australia; Bosentan; Cooperative Behavior; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phenylpropionates; Piperazines; Prospective Studies; Purines; Pyridazines; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Rate; Young Adult | 2011 |
Pulmonary arterial hypertension: combination therapy in the modern management era.
Topics: Adult; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2010 |
Combination therapy for life-threatening pulmonary hypertension in a premature infant: first report on bosentan use.
Topics: Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Female; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Nitric Oxide; Persistent Fetal Circulation Syndrome; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2011 |
Pharmacokinetics of bosentan in routinely treated Japanese pediatric patients with pulmonary arterial hypertension.
Topics: Adolescent; Age Factors; Aryl Hydrocarbon Hydroxylases; Asian People; Bayes Theorem; Body Weight; Bosentan; Child; Child, Preschool; Computer Simulation; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Drug Interactions; Familial Primary Pulmonary Hypertension; Female; Genotype; Heart Failure; Humans; Hypertension, Pulmonary; Infant; Infant, Newborn; Liver-Specific Organic Anion Transporter 1; Male; Models, Biological; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Piperazines; Polymorphism, Single Nucleotide; Purines; Sildenafil Citrate; Solute Carrier Organic Anion Transporter Family Member 1B3; Sulfonamides; Sulfones | 2011 |
Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment.
Topics: Adolescent; Antihypertensive Agents; Bosentan; Child; Child, Preschool; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelium, Vascular; Epoprostenol; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Muscle, Smooth, Vascular; Nifedipine; Nitric Oxide Synthase Type III; Piperazines; Pulmonary Artery; Purines; Receptor, Endothelin A; Receptor, Endothelin B; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2011 |
Improved survival in patients with inoperable chronic thromboembolic pulmonary hypertension.
Topics: Acid-Base Equilibrium; Aged; Antihypertensive Agents; Blood Gas Analysis; Bosentan; Cardiac Output; Chronic Disease; Drug Therapy, Combination; Exercise Test; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Oxygen Consumption; Oxygen Inhalation Therapy; Piperazines; Purines; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Rate; Thiophenes; Thromboembolism; Treatment Outcome; Vascular Resistance; Vasodilator Agents | 2013 |
Late clinical manifestations of mitral valve disease and severe pulmonary hypertension in a patient diagnosed with premature closure of foramen ovale during fetal life.
Topics: Antihypertensive Agents; Bosentan; Cardiac Catheterization; Fetal Diseases; Foramen Ovale; Heart Failure; Heart Valve Prosthesis Implantation; Humans; Hypertension, Pulmonary; Infant, Newborn; Male; Mitral Valve Stenosis; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Failure; Ultrasonography, Doppler, Pulsed; Ultrasonography, Prenatal; Vasodilator Agents | 2011 |
Prevalence of spontaneous portosystemic shunts in patients with portopulmonary hypertension and effect on treatment.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Case-Control Studies; Child; Drug Therapy, Combination; Epoprostenol; Female; Humans; Hypertension, Portal; Hypertension, Pulmonary; Magnetic Resonance Imaging; Male; Mesentery; Middle Aged; Piperazines; Purines; Regional Blood Flow; Renal Veins; Retrospective Studies; Severity of Illness Index; Sildenafil Citrate; Splenic Vein; Sulfonamides; Sulfones; Tomography, Spiral Computed; Treatment Outcome; Vena Cava, Inferior | 2011 |
[Treatment of idiopathic pulmonary arterial hypertension].
Topics: Adult; Airway Resistance; Antihypertensive Agents; Bosentan; Epoprostenol; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Iloprost; Lung Transplantation; Lung Volume Measurements; Male; Middle Aged; Oxygen Consumption; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Pyridazines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2011 |
Combination therapy with an endothelin-1 receptor antagonist (bosentan) and a phosphodiesterase V inhibitor (sildenafil) for the management of severe digital ulcerations in systemic sclerosis.
Topics: Bosentan; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Fingers; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Scleroderma, Systemic; Sildenafil Citrate; Skin Ulcer; Sulfonamides; Sulfones | 2011 |
Screening and treating pulmonary arterial hypertension in a tertiary hospital-based multidisciplinary clinic: the first 200 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allergy and Immunology; Bosentan; Cardiac Catheterization; Cardiology; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Iloprost; Kaplan-Meier Estimate; Male; Mass Screening; Middle Aged; Outpatient Clinics, Hospital; Patient Care Team; Piperazines; Prospective Studies; Pulmonary Medicine; Purines; Rheumatology; Sildenafil Citrate; Sulfonamides; Sulfones; Tertiary Care Centers; Ultrasonography; Young Adult | 2013 |
The management of Eisenmenger syndrome in the modern treatment era: a case report.
Topics: Adult; Antihypertensive Agents; Bosentan; Combined Modality Therapy; Drug Therapy, Combination; Eisenmenger Complex; Exercise Tolerance; Familial Primary Pulmonary Hypertension; Female; Heart Septal Defects, Ventricular; Humans; Hypertension, Pulmonary; Iron, Dietary; Piperazines; Purines; Quality of Life; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2011 |
"Treat-to-target" in pulmonary arterial hypertension and the use of extracorporeal membrane oxygenation as a bridge to transplantation.
Topics: Adult; Antihypertensive Agents; Bosentan; Combined Modality Therapy; Drug Therapy, Combination; Extracorporeal Membrane Oxygenation; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Iloprost; Lung Transplantation; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2011 |
Relation of bosentan, iloprost, and sildenafil with growth factor levels in monocrotaline-induced pulmonary hypertension.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Bosentan; Female; Hypertension, Pulmonary; Iloprost; Monocrotaline; Piperazines; Pulmonary Artery; Purines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Sulfonamides; Sulfones; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A; Vasodilator Agents | 2012 |
Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells.
Topics: Antihypertensive Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Bosentan; Carbolines; Cell Line, Tumor; Cytochrome P-450 CYP3A; Drug Interactions; Endothelin A Receptor Antagonists; Gene Expression Regulation; Genes, Reporter; Humans; Intestinal Absorption; Intestinal Mucosa; Intestines; Peroxisome-Targeting Signal 1 Receptor; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Piperazines; Pregnane X Receptor; Promoter Regions, Genetic; Purines; Pyridazines; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Recombinant Proteins; RNA, Messenger; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil | 2013 |
A case of pulmonary veno-occlusive disease: diagnostic dilemmas and therapeutic challenges.
Topics: Adult; Bosentan; Diagnosis, Differential; Disease Progression; Drug Therapy, Combination; Endothelin Receptor Antagonists; Epoprostenol; Humans; Iloprost; Lung; Lung Transplantation; Male; Piperazines; Pulmonary Artery; Pulmonary Veno-Occlusive Disease; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Tomography, X-Ray Computed; Vasodilator Agents; Waiting Lists | 2013 |
Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan.
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Liver; Liver Function Tests; Middle Aged; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Safety-Based Drug Withdrawals; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes | 2012 |
Long survival of congenital alveolar capillary dysplasia patient with NO inhalation and epoprostenol: effect of sildenafil, beraprost and bosentan.
Topics: Administration, Inhalation; Bosentan; Bronchodilator Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epoprostenol; Fatal Outcome; Female; Follow-Up Studies; Humans; Infant, Newborn; Nitric Oxide; Persistent Fetal Circulation Syndrome; Piperazines; Platelet Aggregation Inhibitors; Pulmonary Alveoli; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Time Factors; Vasodilator Agents | 2012 |
Food and Drug Administration (FDA) postmarket reported side effects and adverse events associated with pulmonary hypertension therapy in pediatric patients.
Topics: Adolescent; Antihypertensive Agents; Bosentan; Child; Child, Preschool; Drug-Related Side Effects and Adverse Reactions; Epoprostenol; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Incidence; Infant; Infant, Newborn; Male; Piperazines; Product Surveillance, Postmarketing; Purines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Sulfones; United States; United States Food and Drug Administration; Vasodilator Agents | 2013 |
Bosentan and sildenafil: successful treatment in a sclerodermic patient with refractory ulcers.
Topics: Bosentan; Endothelin Receptor Antagonists; Female; Humans; Middle Aged; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Remission Induction; Scleroderma, Systemic; Sildenafil Citrate; Skin Ulcer; Sulfonamides; Sulfones | 2013 |
Idiopathic pulmonary arterial hypertension.
Topics: Aminorex; Antihypertensive Agents; Appetite Depressants; Bosentan; Dasatinib; Epoprostenol; Familial Primary Pulmonary Hypertension; Fenfluramine; Genetic Predisposition to Disease; Humans; Hypertension, Pulmonary; Iloprost; Phenylpropionates; Piperazines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridazines; Pyrimidines; Risk Factors; Sildenafil Citrate; Sulfonamides; Sulfones; Thiazoles; Vasodilator Agents | 2013 |
Diagnosis and treatment of pulmonary hypertension in infancy.
Topics: Bosentan; Bronchopulmonary Dysplasia; Hernia, Diaphragmatic; Humans; Hypertension, Pulmonary; Infant, Newborn; Milrinone; Nitric Oxide; Piperazines; Prostaglandins; Purines; Signal Transduction; Sildenafil Citrate; Sulfonamides; Sulfones; Vascular Resistance | 2013 |
Safety and tolerability of targeted therapies for pulmonary hypertension in children.
Topics: Antihypertensive Agents; Bosentan; Child; Child, Preschool; Drug Therapy, Combination; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Infant; Longitudinal Studies; Male; Piperazines; Purines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2014 |
Combination of sildenafil and bosentan for pulmonary hypertension in a human ex vivo model.
Topics: Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelin-1; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Norepinephrine; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasoconstriction | 2014 |
Simultaneous microdetermination of bosentan, ambrisentan, sildenafil, and tadalafil in plasma using liquid chromatography/tandem mass spectrometry for pediatric patients with pulmonary arterial hypertension.
Topics: Bosentan; Carbolines; Child; Child, Preschool; Chromatography, Liquid; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Infant; Male; Phenylpropionates; Piperazines; Purines; Pyridazines; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Tandem Mass Spectrometry | 2014 |
Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre.
Topics: Adolescent; Age Factors; Antihypertensive Agents; Bosentan; Child; Cohort Studies; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Netherlands; Piperazines; Purines; Secondary Care Centers; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2014 |
Combined approach in ventricular septal defect and adult pulmonary hypertension.
Topics: Administration, Inhalation; Adult; Antihypertensive Agents; Bosentan; Cardiac Surgical Procedures; Drug Therapy, Combination; Female; Heart Septal Defects, Ventricular; Humans; Hypertension, Pulmonary; Nitric Oxide; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2013 |
Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Epoprostenol; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pilot Projects; Piperazines; Prognosis; Purines; Registries; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Young Adult | 2014 |
Imatinib is partially effective for the treatment of pulmonary capillary hemangiomatosis.
Topics: Adult; Antihypertensive Agents; Antineoplastic Agents; Autopsy; Benzamides; Bosentan; Cardiac Catheterization; Dyspnea; Echocardiography; Epoprostenol; Fatal Outcome; Hemangioma, Capillary; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Lung; Lung Neoplasms; Male; Piperazines; Purines; Pyrimidines; Radiography, Thoracic; Sildenafil Citrate; Sulfonamides; Treatment Failure | 2014 |
Better off blue: BMPR-2 mutation, arteriovenous malformation, and pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Arteriovenous Malformations; Bone Morphogenetic Protein Receptors, Type II; Bosentan; Disease Progression; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension; Follow-Up Studies; Humans; Hypertension, Pulmonary; Male; Middle Aged; Mutation; Pedigree; Piperazines; Pulmonary Artery; Pulmonary Veins; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2014 |
Clinical and molecular study of 4 cases of pulmonary hypertension associated with sarcoidosis.
Topics: Bone Morphogenetic Protein Receptors, Type II; Bosentan; Disease Progression; Epoprostenol; Fatal Outcome; Female; Humans; Hypertension, Pulmonary; Kv1.5 Potassium Channel; Male; Middle Aged; Mutation; Phenylpropionates; Point Mutation; Pyridazines; Respiratory Function Tests; RNA, Messenger; Sarcoidosis; Sildenafil Citrate; Sulfonamides; Tadalafil; Treatment Outcome | 2015 |
Screening for pulmonary arterial hypertension in patients with scleroderma--a New Zealand perspective.
Topics: Anticoagulants; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Echocardiography; Electrocardiography; Exercise Test; Humans; Hypertension, Pulmonary; Mass Screening; New Zealand; Physical Examination; Piperazines; Practice Patterns, Physicians'; Purines; Respiratory Function Tests; Rheumatology; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Surveys and Questionnaires; Vasodilator Agents | 2014 |
Treatment with a combination of bosentan and sildenafil allows for successful liver transplantation in a patient with portopulmonary hypertension.
Topics: Adult; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Humans; Hypertension, Portal; Hypertension, Pulmonary; Liver Transplantation; Male; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Vasodilator Agents | 2014 |
Determination of the effects of pulmonary arterial hypertension and therapy on the cardiovascular system of rats by impedance cardiography.
Topics: Animals; Blood Pressure; Bosentan; Cardiography, Impedance; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Endothelin Receptor Antagonists; Heart Ventricles; Hypertension, Pulmonary; Male; Monocrotaline; Phosphodiesterase 5 Inhibitors; Piperazines; Pulmonary Artery; Purines; Rats, Wistar; Sildenafil Citrate; Sulfonamides | 2014 |
[The management of adult female patients with Eisenmenger syndrome and advanced pulmonary arterial hypertension treatment: single center experience and follow-up for 5 years].
Topics: Adult; Antihypertensive Agents; Bosentan; Echocardiography; Eisenmenger Complex; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Iloprost; Laser-Doppler Flowmetry; Piperazines; Pulmonary Wedge Pressure; Purines; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Treatment Outcome; Turkey | 2014 |
Antenatal use of bosentan and/or sildenafil attenuates pulmonary features in rats with congenital diaphragmatic hernia.
Topics: Animals; Bosentan; Disease Models, Animal; Female; Hernias, Diaphragmatic, Congenital; Lung; Lung Diseases; Phenyl Ethers; Piperazines; Pregnancy; Purines; Random Allocation; Rats; Rats, Wistar; Sildenafil Citrate; Sulfonamides; Vascular Remodeling | 2014 |
Eisenmenger syndrome with unrepaired patent ductus arteriosus.
Topics: Blood Transfusion; Bosentan; Diagnostic Imaging; Dobutamine; Ductus Arteriosus, Patent; Eisenmenger Complex; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Magnetic Resonance Imaging; Menorrhagia; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Tomography, X-Ray Computed; Vasodilator Agents; Young Adult | 2015 |
Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.
Topics: Adult; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Drug Therapy, Combination; Endothelin Receptor Antagonists; Epoprostenol; Exercise Test; Female; Humans; Hypertension, Pulmonary; Middle Aged; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pilot Projects; Prostaglandins; Pulmonary Wedge Pressure; Pyridazines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Tadalafil; Treatment Outcome; Vascular Resistance; Young Adult | 2015 |
Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Cause of Death; Child; Connective Tissue Diseases; Drug Therapy, Combination; Exercise Test; Familial Primary Pulmonary Hypertension; Female; Heart Defects, Congenital; Hemodynamics; Humans; Hypertension, Pulmonary; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Survival Rate; Treatment Outcome; Vasodilator Agents; Young Adult | 2015 |
Comparison of angiogenic and proliferative effects of three commonly used agents for pulmonary artery hypertension (sildenafil, iloprost, bosentan): is angiogenesis always beneficial?
Topics: Angiogenesis Inducing Agents; Animals; Bosentan; Cell Proliferation; Chick Embryo; Dose-Response Relationship, Drug; Human Umbilical Vein Endothelial Cells; Humans; Hypertension, Pulmonary; Iloprost; Sildenafil Citrate; Sulfonamides | 2015 |
Navigating the uncharted waters of combination therapy in pulmonary arterial hypertension: COMPASS or dead-reckoning.
Topics: Antihypertensive Agents; Bosentan; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Sildenafil Citrate; Sulfonamides; Vasodilator Agents | 2015 |
Severe pulmonary hypertension associated with COPD: hemodynamic improvement with specific therapy.
Topics: Aged; Bosentan; Cohort Studies; Comorbidity; Female; Follow-Up Studies; France; Hemodynamics; Hospitals, University; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Retrospective Studies; Severity of Illness Index; Sildenafil Citrate; Statistics, Nonparametric; Sulfonamides; Treatment Outcome; Vascular Resistance; Vasodilator Agents | 2015 |
Potential Role of CT Metrics in Chronic Obstructive Pulmonary Disease with Pulmonary Hypertension.
Topics: Aged; Bosentan; Endothelin Receptor Antagonists; Exercise Test; Female; Forced Expiratory Volume; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Artery; Pulmonary Diffusing Capacity; Pulmonary Disease, Chronic Obstructive; Pulmonary Fibrosis; Sildenafil Citrate; Sulfonamides; Tadalafil; Tomography, X-Ray Computed; Vasodilator Agents; Vital Capacity | 2015 |
Use of Pulmonary Hypertension Medications in Patients with Tetralogy of Fallot with Pulmonary Atresia and Multiple Aortopulmonary Collaterals.
Topics: Abnormalities, Multiple; Adolescent; Antihypertensive Agents; Bosentan; Catheterization; Child; Child, Preschool; District of Columbia; Echocardiography; Female; Hemodynamics; Hospitals, Pediatric; Humans; Hypertension, Pulmonary; Infant; Infant, Newborn; Lung; Male; Phenylpropionates; Pulmonary Artery; Pulmonary Atresia; Pyridazines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Tertiary Care Centers; Tetralogy of Fallot; Young Adult | 2016 |
Dried Blood Spot Technique for the Monitoring of Ambrisentan, Bosentan, Sildenafil, and Tadalafil in Patients with Pulmonary Arterial Hypertension.
Topics: Bosentan; Chromatography, Liquid; Dried Blood Spot Testing; Humans; Hypertension, Pulmonary; Limit of Detection; Phenylpropionates; Pyridazines; Reproducibility of Results; Sildenafil Citrate; Sulfonamides; Tadalafil; Tandem Mass Spectrometry | 2015 |
Combination therapy with Bosentan and Sildenafil improves Raynaud's phenomenon and fosters the recovery of microvascular involvement in systemic sclerosis.
Topics: Adult; Aged; Bosentan; Capillaries; Drug Therapy, Combination; Female; Humans; Male; Microscopic Angioscopy; Microvessels; Middle Aged; Nails; Raynaud Disease; Retrospective Studies; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Treatment Outcome; Vasodilator Agents | 2016 |
Novel homozygous BMP9 nonsense mutation causes pulmonary arterial hypertension: a case report.
Topics: Anticoagulants; Antihypertensive Agents; Bosentan; Child, Preschool; Codon, Nonsense; Epoprostenol; Growth Differentiation Factor 2; Growth Differentiation Factors; Homozygote; Humans; Hypertension, Pulmonary; Male; Mexican Americans; Sildenafil Citrate; Sulfonamides; Vasodilator Agents; Warfarin | 2016 |
First data from Latvian chronic thromboembolic pulmonary hypertension registry.
Topics: Adult; Age Distribution; Aged; Anticoagulants; Bosentan; Chronic Disease; Female; Humans; Hypertension, Pulmonary; Incidence; Latvia; Male; Middle Aged; Phenylpropionates; Prevalence; Pulmonary Embolism; Pyrazoles; Pyridazines; Pyridones; Registries; Rivaroxaban; Sex Distribution; Sildenafil Citrate; Sulfonamides; Vasodilator Agents; Warfarin; Young Adult | 2016 |
Initial dual oral combination therapy in pulmonary arterial hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Diethylpropion; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Patient Safety; Phenylpropionates; Pyridazines; Retrospective Studies; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Tadalafil; Time Factors; Treatment Outcome | 2016 |
Pulmonary hypertension specific treatment in infants with bronchopulmonary dysplasia.
Topics: Antihypertensive Agents; Bosentan; Bronchopulmonary Dysplasia; Child, Preschool; Drug Therapy, Combination; Echocardiography; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Infant; Infant, Newborn; Male; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Treatment Outcome | 2017 |
Physicochemical Properties of Bosentan and Selected PDE-5 Inhibitors in the Design of Drugs for Rare Diseases.
Topics: Bosentan; Drug Design; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Rare Diseases; Sildenafil Citrate; Sulfonamides; Tadalafil | 2017 |
Non-healing ischaemic digital ulcer in a systemic sclerosis patient: a challenging clinical case.
Topics: Administration, Intravenous; Administration, Oral; Bosentan; Botulinum Toxins, Type A; Cross-Sectional Studies; Female; Fingers; Humans; Iloprost; Middle Aged; Phosphodiesterase 5 Inhibitors; Scleroderma, Systemic; Sildenafil Citrate; Skin Ulcer; Sulfonamides; Treatment Outcome; Wound Healing | 2017 |
Superior vasodilation of human pulmonary vessels by vardenafil compared with tadalafil and sildenafil: additive effects of bosentan.
Topics: Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Pulmonary Artery; Pulmonary Veins; Sildenafil Citrate; Sulfonamides; Tadalafil; Vardenafil Dihydrochloride; Vasodilation; Vasodilator Agents | 2017 |
Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
Topics: Adult; Aged; Bosentan; Case-Control Studies; Drug Interactions; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pyridazines; Pyrimidines; Sildenafil Citrate; Sulfonamides; Tadalafil | 2017 |
Outcomes of pulmonary arterial hypertension therapy in Australia: is monotherapy adequate?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Australia; Bosentan; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prospective Studies; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Treatment Failure; Young Adult | 2017 |
Improvement of peripheral artery disease with Sildenafil and Bosentan combined therapy in a patient with limited cutaneous systemic sclerosis: A case report.
Topics: Bosentan; Cardiovascular Agents; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Middle Aged; Peripheral Arterial Disease; Phosphodiesterase 5 Inhibitors; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides | 2017 |
Clinical and histopathological relationship of sildenafil and bosentan treatments in rats with monocrotaline induced pulmonary hypertension.
Topics: Animals; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Hypertension, Pulmonary; Lung; Male; Monocrotaline; Phosphodiesterase 5 Inhibitors; Rats; Rats, Wistar; Sildenafil Citrate; Sulfonamides | 2017 |
Cardiopulmonary anomalies in incontinentia pigmenti patients.
Topics: Antihypertensive Agents; Bosentan; Female; Humans; Hypertension, Pulmonary; Incontinentia Pigmenti; Infant, Newborn; Oxygen Inhalation Therapy; Sildenafil Citrate; Sulfonamides; Vasodilator Agents | 2018 |
German Guideline for Idiopathic Pulmonary Fibrosis - Update on Pharmacological Therapies 2017.
Topics: Acetylcysteine; Adult; Aged; Aged, 80 and over; Antacids; Bosentan; Clinical Trials as Topic; Evidence-Based Medicine; Female; Gastroesophageal Reflux; Guideline Adherence; Humans; Idiopathic Pulmonary Fibrosis; Imatinib Mesylate; Indoles; Male; Middle Aged; Phenylpropionates; Pyridazines; Pyridones; Pyrimidines; Sildenafil Citrate; Sulfonamides | 2018 |
Sildenafil-Bosentan Drug-Drug Interaction: A Word of Caution Regarding the Most Common Combination Therapy in Children with Advanced Pulmonary Arterial Hypertension.
Topics: Bosentan; Child; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Sildenafil Citrate | 2018 |
Pulmonary Arterial Hypertension Specific Therapy in Patients with Combined Post- and Precapillary Pulmonary Hypertension.
Topics: Analysis of Variance; Antihypertensive Agents; Bosentan; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies; Sildenafil Citrate; Treatment Outcome; Vasodilator Agents; Walking | 2018 |
Choice of Initial Oral Therapy for Pulmonary Arterial Hypertension: Age and Long-Term Survival.
Topics: Administration, Oral; Age Factors; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pyridazines; Pyrimidines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Tadalafil | 2018 |
Bosentan or Macitentan Therapy in Chronic Thromboembolic Pulmonary Hypertension?
Topics: Aged; Bosentan; Chronic Disease; Drug Therapy, Combination; Endarterectomy; Endothelin Receptor Antagonists; Enzyme Activators; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Phosphodiesterase 5 Inhibitors; Pulmonary Embolism; Pyrazoles; Pyrimidines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Survival Rate; Walk Test | 2019 |
Presumed prenatal closure of foramen ovale and persistent pulmonary hypertension of the newborn.
Topics: Bosentan; Echocardiography; Female; Foramen Ovale; Heart Failure; Humans; Hypertension, Pulmonary; Infant, Newborn; Male; Pregnancy; Sildenafil Citrate; Treatment Outcome; Ultrasonography, Prenatal | 2020 |
Characteristics of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis and Anticentriole Autoantibodies.
Topics: Aged; Aged, 80 and over; Antibodies, Antinuclear; Autoantibodies; Bosentan; Cardiac Catheterization; Centrioles; Drug Therapy, Combination; Endothelin Receptor Antagonists; Epoprostenol; Female; Forced Expiratory Volume; Humans; Imatinib Mesylate; Protein Kinase Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Diffusing Capacity; Pyrimidines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Tadalafil; Tomography, X-Ray Computed; Vasodilator Agents | 2020 |
Chronic lung disease-associated PH: PAH-approved drugs and established universal healthcare insurance in Japan.
Topics: Bosentan; Humans; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Insurance Coverage; Japan; Phenylpropionates; Prevalence; Prognosis; Pulmonary Disease, Chronic Obstructive; Pyrazoles; Pyridazines; Pyrimidines; Sildenafil Citrate; Sulfonamides; Treatment Outcome; Universal Health Insurance | 2020 |
More than a rare cause of pulmonary hypertension in the elderly.
Topics: Aged, 80 and over; Bosentan; Computed Tomography Angiography; Coronary Vessel Anomalies; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Pulmonary Artery; Scimitar Syndrome; Sildenafil Citrate; Treatment Outcome | 2020 |
Pulmonary Vasodilator Therapy in Children with Single Ventricle Physiology: Effects on Saturation and Pulmonary Arterial Pressure.
Topics: Adolescent; Arterial Pressure; Bosentan; Child; Child, Preschool; Drug Therapy, Combination; Exercise Tolerance; Female; Heart Defects, Congenital; Heart Ventricles; Humans; Hypertension, Pulmonary; Infant; Male; Retrospective Studies; Sildenafil Citrate; Treatment Outcome; United Kingdom; Vascular Resistance; Vasodilator Agents | 2020 |
Effectiveness of oral sildenafil for neonates with persistent pulmonary hypertension of newborn (PPHN): a prospective study in a tertiary care hospital.
Topics: Bosentan; Child; Humans; Infant, Newborn; Nitric Oxide; Persistent Fetal Circulation Syndrome; Prospective Studies; Sildenafil Citrate; Tertiary Care Centers; Vasodilator Agents | 2022 |